To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Local Injection of Ketorolac vs Triamcinolone Acetonide for De Quervain's Tenosynovitis

Download
Share
Reprints
Cite This
About
+ Favorites
Download
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
November 2022

Local Injection of Ketorolac vs Triamcinolone Acetonide for De Quervain's Tenosynovitis

Vol: 299| Issue: 1| Number:1| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Comparison of the effect of ketorolac versus triamcinolone acetonide injections for the treatment of de Quervain's tenosynovitis: a double-blind randomized controlled trial

BMC Musculoskelet Disord. 2022 Sep 1;23(1):831.

Contributing Authors:
S Suwannaphisit P Suwanno W Fongsri C Chuaychoosakoon

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

Sixty-four patients with de Quervain's tenosynovitis were randomized to receive a local injection of ketorolac (n=31) or triamcinolone acetonide (n=33). Outcomes of interest included pain scores on a Visual Numeric Rating Scale (VNRS), the Disabilities of the Arm, Shoulder and Hand (DASH) score, grip strength and pinch strength, and the need for additional injection, assessed at 6 weeks follow up....

Join the Conversation

Please Login or Join to leave comments.